Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(20):1625; doi:10.1093/jnci/92.20.1625
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 20, 1625, October 18, 2000
© 2000 Oxford University Press

IN THIS ISSUE

Mechanism for Resistance to the Drug STI571

The tyrosine kinase Bcr-Abl, which causes chronic myeloid leukemia, can be inhibited by the drug STI571. Mice injected with human leukemic cells can be cured with STI571, but treatment ultimately fails in animals that have large tumors. Gambacorti-Passerini et al. (p. 1641) explored the mechanism of this drug resistance in mice that relapsed after STI571 treatment. Tumor cells isolated from these animals were still sensitive to STI571, suggesting that a plasma protein may be inactivating STI571. They found that {alpha}1 acid glycoprotein (AGP) bound STI571 and blocked its . . . [Full Text of this Article]

Assessing the Risk of False-Positive Mammograms

Passive Smoking Exposure and Breast Cancer Mortality

Breast Cancer Resistance Protein and Topotecan

CYP17 Gene Polymorphism and Breast Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?